Torrent Pharmaceuticals | Sustainability Performance
Develops and markets branded and generic pharmaceutical products.
1959
India
10,001+ employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#11268
Overallⓘ#347
in Indiaⓘ#271
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Laggard
Laggard
Leading
Controversy level
- Torrent Pharmaceuticals Limited, Indian major pharma (Sudhir Mehta family), has faced sustained Indian CDSCO and US FDA enforcement scrutiny including multiple FDA warning letters at the Indrad and Dahej production facilities, plus periodic class actions over alleged inadequate disclosure of US generic pharma customer concentration affecting Indian institutional shareholders amid Indian generic pharma sector regulatory pressure.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
2-3
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.